Product Name
Gardiquimod (TLR7 agonist/Imidazoquinoline), antigen grade
Subclassification
Vaccine grade-PRR Ligands-based adjuvant
Storage
Shipped at room temperature and it should be stored at room temp. DO NOT FREEZE. Stable for 6 months.
Recommended Usage
Stimulation of TLR7 can be achieved with 0.1-3 µg/ml Gardiquimod. 24 to 48 hours after transfection, stimulate cells with 0.1-3 µg/ml Gardiquimod™ for 6 to 24 hours. Cell lines that do not express TLR7 naturally should be cotransfected with a TLR7 expressing plasmid.
Add 5 ml water to 5 mg Gardiquimod™ vial and vortex until complete solubilization.
*For in vitro research use only*
Description
Toll-like receptors (TLRs) are a family of highly conserved germlineencoded pattern-recognition receptors that are essential for host immune responses. TLR ligands represent a promising class of immunotherapeutics or vaccine adjuvants with the potential to generate an effective antitumor immune response. The TLR7/8 agonists have aroused interest because they not only activate antigen-presenting cells but also promote activation of T and natural killer (NK) cells.
Gardiquimod is a selective ligand for human or mouse Toll-like receptor 7 (TLR7). Induces the activation of NF-κB in HEK 293 cells expressing TLR7. At high concentrations (3 mg/ml), slightly activates TLR8.
Formulation: C17H23N5O
Hazard: TOXIC:
Format
Gardiquimod is supplied as a sterile lyophililized powder. White to off-white solid.
Loading ......
